Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer
Boman Dhabhar
DOI: https://doi.org/10.2147/BCTT.S353332
2022-07-14
Breast Cancer: Targets and Therapy
Abstract:Boman Dhabhar Department of Medical Oncology, Fortis Hospital, Mumbai, India Correspondence: Boman Dhabhar, Consultant, Medical Oncology, Fortis Hospital, Mulund, Mumbai, 400078, Maharashtra, India, Email Chemotherapeutic agents, endocrine therapy and radiotherapy used in the management of breast cancer are known to cause decreased bone mineral density, and thus, increased incidence of fractures. A majority (∼ 60%) of the breast cancer patients in India are either estrogen (ER) or progesterone hormone receptor (PR) positive. Adjuvant treatment with aromatase inhibitors (AIs) is the treatment mainstay for hormone-sensitive disease in postmenopausal (PM) women, with reduced bone mineral density (BMD), which results in increased fracture rates. Zoledronic acid, alendronate, risedronate and denosumab have been the agents of choice for managing bone loss. Denosumab 60 mg is approved for gaining bone mass in women with breast cancer who are at high risk for fracture following adjuvant AI treatment. The phase III HALT-BC data indicate an improvement in BMD with denosumab and a 50% reduction in clinical fractures, with significant improvements seen at the lumbar spine, distal third of the radius, and total hip. Denosumab has several advantages over other bone modifying agents such as subcutaneous self-administration by the patient themselves, no requirement of hospitalization, no dose modifications in renal impairment, and low incidence of acute phase anaphylactic reactions. We review the available evidence of denosumab for managing bone loss in non-metastatic breast cancer patients. Keywords: nonmetastatic breast cancer, postmenopausal women, denosumab, bone loss, bone mineral density, fracture Globally, breast cancer is one of the most commonly diagnosed cancer, and the leading cause of mortality in women with cancer. 1,2 Of all the cancer cases worldwide, 11.7% cases are breast cancer, of which 2,261,419 cases are newly diagnosed and 684,996 (6.9%) deaths reported, as per GLOBOCAN 2020. 3 In India, the incidence of breast cancer was 26.3% (178,361 cases) in 2020, which is highest among all other cancers in women. 4 Postmenopausal (PM) breast cancer accounts for ~80% of all newly diagnosed breast cancers. 5 Approximately 75–80% of the breast cancer cases are hormone-receptor (HR; either estrogen [ER] or progesterone [PR]) positive. 6,7 In India, 50–60% of breast cancer patients are HR-positive. 8–10 The American Society of Clinical Oncology and the European Society of Medical Oncology guidelines recommend oophorectomy or adjuvant therapy with endocrine agents in HR-positive disease to prevent recurrence or developing new breast cancer. These include selective ER modulators (SERMs), agonists for luteinizing hormone (LH)-releasing hormone (LHRH) and aromatase inhibitors (AIs). 6,11–13 The extensive use of adjuvant endocrine treatment has led to reduced mortality in HR-positive early breast cancer (EBC). 7 There is an increased risk of breast cancer occurrence in individuals with advanced age, particularly after 60 years, 14 who also have a high risk of developing osteoporosis. There is also a high risk of osteoporosis in breast cancer patients with low estrogen levels. Low estrogen levels cause an increased rate of bone resorption leading to decreased levels of bone mineral density (BMD), resulting in osteoporosis and increased fracture risk. 6,15,16 In the healthy state, osteoblast-led bone formation and osteoclast-led resorption of bone are balanced, 17 but in breast cancer, there is an increased osteoclastic activity attributable to the raised transforming growth factor, cytokine, parathyroid hormone-related protein, tumor necrosis factor, insulin-like growth factor 1, and interleukin (IL)-1 and 6 levels. 18,19 The increased risk of osteoporosis and fractures is observed in breast cancer patients with advanced age (>60 years), and low estrogen levels due to hormonal treatment or loss of ovarian function, especially in premenopausal women, due to several medications or surgical interventions. 6,14–16,20 In PM women, a decreased bone density is observed due to natural physiological decline in estrogen levels. 21 The Women's Health Initiative evaluated the incidence of fractures before and after cancer diagnosis in 146,959 PM women who did not have cancer history at baseline. A 9-year follow-up data reported a 55% higher fracture risk in women after diagnosis of breast cancer vs women who remained cancer-free. 5 Furthermore, chemotherapy, radiotherapy, endocrine therapy, and several other medications such as glucocorticoids have been linked with bone loss in PM breast cancer patients. 16,22 Gonadotropin-releasing hormone (GnRH) agonists decrease -Abstract Truncated-